Europe’s battery startups keep hitting the same wall: expensive power, slower scaling, heavy capex, and relentless price ...

SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...

As the CGT market evolves, developers must answer one key question that will shape their manufacturing strategy: “Should we go with a modular platform or a fully integrated system?”  Both approaches ...

Ottawa, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The global cell and gene therapy manufacturing market size was calculated at USD 21.15 billion in 2025 and is expected to reach around USD 215.18 billion by ...

The global market for N-TOPCon Cells was valued at USD 10020 Million in the year 2024 and is projected to reach a revised size of U ...

When most people think of cancer care, they rarely associate it with what goes on behind the scenes to create life-saving treatments. For starters, developing cell and gene therapies is pricey, and ...

DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...

Few robotics technologies have been actually deployed in high-mix manufacturing. Let's explore the reasons behind this slow transition.